Skip to main content
Top
Published in: BMC Gastroenterology 1/2018

Open Access 01-12-2018 | Research article

ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation

Authors: Naim Abu-Freha, Wafi Badarna, Ina Sigal-Batikoff, Muhammad Abu Tailakh, Ohad Etzion, Jaber Elkrinawi, Arik Segal, Alex Mushkalo, Alex Fich

Published in: BMC Gastroenterology | Issue 1/2018

Login to get access

Abstract

Background

Serological markers used for diagnostic purposes and disease stratification in inflammatory bowel disease.
We aimed to investigate the frequency of ASCA and ANCA among Arab Bedouin IBD patients and its relationship to disease phenotype and course.

Methods

From cohort of 68, 25 Crohn’s disease (CD) and 25 Ulcerative colitis (UC) patients were recruited (72%). ASCA IgG was determined by ELISA assay. Immunofluorescence analysis of ANCA was performed.

Results

The IgG ASCA was detected in 13 (52%) of the CD patients and in three (12%) UC patients. The prevalence of ANCA among UC patients was positive with 76%, sub-grouped, atypical ANCA in 9 patients (36%), pANCA in six patients (24%) and cANCA in 4 patients (16%).
The detection of ASCA among CD patients was found not to be a reliable predictor of young age at diagnosis, gender, ileal involvement, anti-TNF treatment or surgery.
UC patients with positive ANCA were younger, mean age 40.2 ± 11.9 compared with 57.3 ± 21.2 (p = 0.03), and diagnosed at a younger age, 29.2 ± 11.8 compared with 43.5 ± 15.3 (p = 0.05).

Conclusion

The frequency of ASCA among Bedouin CD patients and ANCA among UC patients was high, however ASCA was not found to have a predictive value for disease phenotype or course. Positive ANCA in UC patients was predictive for younger age and age at diagnosis.
Literature
2.
go back to reference Abu Freha N, Schwartz D, Elkrinawi J, Ben Yakov G, Abu Tailakh M, Munteanu D, et al. Inflammatory bowel disease among Bedouin Arab in southern Israel. Urbanization and increasing prevalence rates. Eur J Gastroenterol Hepatol. 2015;27(3):230–4.CrossRef Abu Freha N, Schwartz D, Elkrinawi J, Ben Yakov G, Abu Tailakh M, Munteanu D, et al. Inflammatory bowel disease among Bedouin Arab in southern Israel. Urbanization and increasing prevalence rates. Eur J Gastroenterol Hepatol. 2015;27(3):230–4.CrossRef
3.
go back to reference Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ. 1998;297:1105–6.CrossRef Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ. 1998;297:1105–6.CrossRef
4.
go back to reference Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, et al. Addendum to the international consensus statement on testing and reporting of Antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendation for testing in other autoimmune disease. Am J Clin Pathol. 2003;120:312–8.CrossRef Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, et al. Addendum to the international consensus statement on testing and reporting of Antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendation for testing in other autoimmune disease. Am J Clin Pathol. 2003;120:312–8.CrossRef
5.
go back to reference Kallenberg CGM, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol. 2006;2:661–70.CrossRef Kallenberg CGM, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol. 2006;2:661–70.CrossRef
6.
go back to reference Editorial. Rational use of ANCA in diagnosis of vasculitis. Rheumatology. 2002;41:481–3.CrossRef Editorial. Rational use of ANCA in diagnosis of vasculitis. Rheumatology. 2002;41:481–3.CrossRef
7.
go back to reference Papp M, Altorjay I, Lakos G, Tumpek J, Sipka S, Dinya T, et al. Evaluation of the combined application of ethanol-fixed and formaldeyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Clin Vaccine Immunol. 2009;16(4):464–70.CrossRef Papp M, Altorjay I, Lakos G, Tumpek J, Sipka S, Dinya T, et al. Evaluation of the combined application of ethanol-fixed and formaldeyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Clin Vaccine Immunol. 2009;16(4):464–70.CrossRef
8.
go back to reference Lochman I, Kral V, Lochmanova A, Lupač J, Cebecauer L. ANCA in the diagnosis of neutrophil-mediated inflammation. Autoimmun Rev. 2011;10:295–8.CrossRef Lochman I, Kral V, Lochmanova A, Lupač J, Cebecauer L. ANCA in the diagnosis of neutrophil-mediated inflammation. Autoimmun Rev. 2011;10:295–8.CrossRef
9.
go back to reference Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-Saccharomuces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788–91.CrossRef Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-Saccharomuces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788–91.CrossRef
10.
go back to reference Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, et al. Evaluation of serologic disease marker in a population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2001;7:192–201.CrossRef Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, et al. Evaluation of serologic disease marker in a population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2001;7:192–201.CrossRef
11.
go back to reference Peeters M, Joossens S, Vermeirs S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disese. Am J Gastroentol. 2001;96:730–4.CrossRef Peeters M, Joossens S, Vermeirs S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disese. Am J Gastroentol. 2001;96:730–4.CrossRef
12.
go back to reference Mokrowiecka A, Daniel P, Slomka M, Majak P, Malecka-Panas E. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastreoenterology. 2009;56(89):162–6. Mokrowiecka A, Daniel P, Slomka M, Majak P, Malecka-Panas E. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastreoenterology. 2009;56(89):162–6.
13.
go back to reference Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, et al. Anti-Saccharamyces cerevisiae antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232–6.CrossRef Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, et al. Anti-Saccharamyces cerevisiae antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232–6.CrossRef
14.
go back to reference Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007;13(14):2028–36.CrossRef Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007;13(14):2028–36.CrossRef
15.
go back to reference Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogenous subgroups with distinct clinical characteristics. Gut. 2000;47:487–96.CrossRef Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogenous subgroups with distinct clinical characteristics. Gut. 2000;47:487–96.CrossRef
16.
go back to reference Sastegni R, Daperno M, Ercole E, Rigazio C, Bresso F, Masoero G, et al. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn’s disease: is it a reliable diagnostic and prognostic marker. Dig Liver Dis. 2001;33:755–61.CrossRef Sastegni R, Daperno M, Ercole E, Rigazio C, Bresso F, Masoero G, et al. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn’s disease: is it a reliable diagnostic and prognostic marker. Dig Liver Dis. 2001;33:755–61.CrossRef
17.
go back to reference Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53:1117–22.CrossRef Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53:1117–22.CrossRef
18.
go back to reference Zhang Z, Li C, Zhao X, Lv C, He Q, Lei S, et al. Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis Sci. 2012;57:2944–54.CrossRef Zhang Z, Li C, Zhao X, Lv C, He Q, Lei S, et al. Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis Sci. 2012;57:2944–54.CrossRef
19.
go back to reference Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(A):5A–36A.CrossRef Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(A):5A–36A.CrossRef
22.
go back to reference Saadah O, Al-Mughales J. Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia. Arab J Gastroenterol. 2013;14:78–82.CrossRef Saadah O, Al-Mughales J. Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia. Arab J Gastroenterol. 2013;14:78–82.CrossRef
23.
go back to reference Kvehaugen AS, Aasbrenn M, Farup PG. Anti-Saccharomyces cerevisiae antibodies (ASCA) are associated with body fat mass and systemic inflammation, but not with dietary yeast consumption: a cross-sectional study. BMC Obes. 2017;4:28.CrossRef Kvehaugen AS, Aasbrenn M, Farup PG. Anti-Saccharomyces cerevisiae antibodies (ASCA) are associated with body fat mass and systemic inflammation, but not with dietary yeast consumption: a cross-sectional study. BMC Obes. 2017;4:28.CrossRef
24.
go back to reference Abu-Saad K, Shahar DR, Vardi H, Fraser D. Importance of ethnic foods as predictors of and contributors to nutrient intake levels in a minority population. Eur J Clin Nutr. 2010;64(3):S88–94.CrossRef Abu-Saad K, Shahar DR, Vardi H, Fraser D. Importance of ethnic foods as predictors of and contributors to nutrient intake levels in a minority population. Eur J Clin Nutr. 2010;64(3):S88–94.CrossRef
25.
go back to reference Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, Roblin X, et al. Systemic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF ab) in the prediction of IBD patient's outcomes. Autoimmun Rev. 2015;14:231–45.CrossRef Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, Roblin X, et al. Systemic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF ab) in the prediction of IBD patient's outcomes. Autoimmun Rev. 2015;14:231–45.CrossRef
26.
go back to reference Mokhtarifar A, Ganji A, Sadrneshin M, Bahari A, Esmaeilzadeh A, Ghafarzadegan K, et al. Diagnostic value of ASCA ant atypical p-ANCA in differential diagnosis of inflammatory bowel disease. Middle East J Dig Dis. 2013;5:93–7.PubMedPubMedCentral Mokhtarifar A, Ganji A, Sadrneshin M, Bahari A, Esmaeilzadeh A, Ghafarzadegan K, et al. Diagnostic value of ASCA ant atypical p-ANCA in differential diagnosis of inflammatory bowel disease. Middle East J Dig Dis. 2013;5:93–7.PubMedPubMedCentral
27.
go back to reference Bouzid D, Haddouk S, Amouri A, Ben Hadj Hmida Y, Tahri N, Masmoudi H. Contribution of immunofluorescence to identification and characterization of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Indian J Gastroenterol. 2011;30:229–32.CrossRef Bouzid D, Haddouk S, Amouri A, Ben Hadj Hmida Y, Tahri N, Masmoudi H. Contribution of immunofluorescence to identification and characterization of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Indian J Gastroenterol. 2011;30:229–32.CrossRef
Metadata
Title
ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation
Authors
Naim Abu-Freha
Wafi Badarna
Ina Sigal-Batikoff
Muhammad Abu Tailakh
Ohad Etzion
Jaber Elkrinawi
Arik Segal
Alex Mushkalo
Alex Fich
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2018
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-018-0884-x

Other articles of this Issue 1/2018

BMC Gastroenterology 1/2018 Go to the issue